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Introduction
Many aspects of the usual paradigm for the clinical development of cytotoxic anti-cancer drugs are not appropriate for therapeutic cancer vaccines (1) . In this chapter we explore some of these differences and recommend designs and strategies more suited for the development of effective therapeutic vaccines.
Dose-Escalation Studies
Safety Studies
Phase I studies usually involve dose escalation in cohorts of three patients, starting with a very low dose, in an effort to identify a maximally tolerated dose. Phase I studies are generally conducted in patients with advanced metastatic disease who have failed all other available treatments. Tumor vaccines are often based on DNA constructs, viral vectors and cytokines that have been determined as safe in previous clinical trials.
Peptide vaccines generally seem inherently safe as long as the cytokine adjuvants are used in combinations and doses previously demonstrated to be safe. Consequently, no phase I safety study should be required for most therapeutic cancer vaccines.
On the other hand, a novel virus or plasmid used as a recombinant vaccine vector for the first time should be evaluated for safety. A dose escalation design may be appropriate but patients whose immune systems have not been compromised by extensive chemotherapy are the most relevant subjects. If such vectors are proven to be nontoxic at substantial doses, then subsequent dose-escalation safety trials using the same vectors but with different recombinant inserts may not be required.
Immunogenicity Studies
Feasibility issues limit the maximum doses of certain vaccines that can be produced for administration to patients. In many cases, the dose selected will be based on pre-clinical findings or on practical considerations.
For cancer vaccines, it is not always the case that more is better. In studies of peptide vaccines based on non-mutated melanoma antigens, in vitro analysis did not reveal any correlation between peptide dose and the generation of specific T cell reactivity from the peripheral blood lymphocytes of vaccinated patients (2, 3) . Thus, for subsequent trials using similar peptides, an intermediate fixed dose of 1 mg was chosen for vaccination, bypassing repetitive phase I studies.
Dose ranging to find the minimal active dose may be feasible but the 3-6 patients per dose level used in conventional toxicity trials may not be adequate. Those small sample sizes are only sufficient to exclude high toxicity rates. Suppose that an assay is used in a binary manner to define immunogenic response. Table 1 shows the probability of no immunogenic responses in n patients as a function of the true immunogenic response probability. If one wants a dose at which the immunogenic response probability is at least 30% say, then if you observe no immunogenic responses in 7 patients it would be appropriate to escalate to the next dose level. (5) . Larger sample sizes are required to detect smaller differences. Using more than two dose levels allows one to treat somewhat fewer patients at each dose level, but the total number of patients required to detect a doseresponse relationship will actually be much larger than if only two dose levels are tested. This is because the two most extreme dose groups are the most informative for detecting a dose-response relationship.
Trying to characterize the shape of the dose-activity relationship or finding an optimum biologic dose is an even more ambitious objective that is rarely practical in a phase I tumor vaccine study.
Phase II Studies
The general objectives of the phase II vaccine trial are similar to those of the phase II cytotoxic trial. The primary objective is to determine whether the regimen has biologic activity that is likely to translate into patient benefit. The second objective is to optimize the regimen.
With cytotoxics, the generally accepted endpoint for phase II trials is objective tumor response; that is, tumor shrinkage by at least 50%. Tumor shrinkage is not a direct measure of patient benefit, although it sometimes is predictive of benefit. The most commonly accepted direct measures of patient benefit are survival, disease free survival and symptomatic relief. Therapeutic effect on these endpoints cannot be reliably established outside of a phase III trial with an appropriate control group not receiving the experimental therapy. Investigators sometimes like to infer that a regimen prolongs survival because the responders live longer than the non-responders, but this analysis has long been known to be invalid (6,7). At the conclusion of the clinical trial, the regimen will be declared active or inactive. Table 2 shows several designs with 10% false positive rate, 10% false negative rate and p 0 =0.05. The false positive rate (α) is the probability of declaring the regimen active when the true response probability is p 0 . The false negative rate (β) is the probability of declaring the regimen inactive when its true response probability is the target response rate p 1, the level of activity that we wish to be able to detect. Otherwise, accrual is continued to a total of 24 patients. If at least 3 responses are seen in the 24 patients, the regimen is declared active. The probability of declaring a regimen active when it's true response rate is 5% or less is 10%. The probability of missing the activity of a regimen with a true response rate of 25% is 10%. With a regimen having a response rate of 5%, the probability of stopping after only 9 patients is 63%. This design with p 1 = 25% and p 0 = 5% seems reasonable for many initial vaccine trials using tumor regression as endpoint. because of lack of clinical responses, the immunological activity of the regimen for the 9 patients accrued will provide information for modifications of the vaccine regimen.
Multiple Arm Screening Trials Using Immunological Response Rate
One of the complexities of therapeutic vaccine development is the many options available for attempting to enhance immunological recognition of a specified tumor antigen. In addition to the vector or mode of presentation of the antigen to the immune system, there are alternative adjuvants, preparative regimens, routes and schedules of administration.
Because of the difficulty and time required for clinical trials, it is best to optimize vaccines to the extent possible using animal models. Nevertheless, there may be several vaccine candidates available for clinical trial. One approach would be to perform a twostage 9-24 patient clinical trial on all candidate regimens, stopping at 9 patients unless partial remissions are seen. An alternative strategy is to perform a multi-arm phase II trial to optimize the regimen with regard to immunogenicity before focusing on clinical endpoints. The reason for using a multi-arm randomized phase II design is to ensure comparability of patients on the different regimens and to control for assay variability. 
where z z/2 is the 100(α/2)'th percentile of the standard normal distribution and z β is the 100β'th percentile. For 5% type 1 error and 80% power, we have z α/2 =1.96 and z β =0.84.
To detect a difference in means that represents one standard deviation of inter-patient variability in immunogenicity requires N=32 patients randomized. This gives 16 patients in each level of each binary factor. With 3 binary factors, there are 8 treatment groups.
Hence randomly assigning 4 patients per treatment group will satisfy this requirement.
The required sample size is very dependent on the δ/σ ratio. Reducing σ by improving the assay reproducibility will increase this ratio for a fixed δ. The quantity σ reflects both biological variability and assay variability, and so using a more homogeneous group of patients may also serve to reduce σ.
Randomized Selection Design
An alternative approach to optimizing a vaccine regimen is to conduct a randomized phase II trial of the variants and to select the regimen that has the best average immunogenicity in the trial. This type of approach has been described by Simon et al.
(16), Strauss and Simon (17) and Yao et al. (18). The analysis does not result in any
conclusions of which factors are important to immunogenicity or which regimens are significantly better than which other regimens, but merely a selection of a regimen which is most promising for further investigation. There are two approaches to establishing sample size per treatment group for such selection designs. One approach, described in Simon et al. (16) is to require that the sample size per treatment be large enough to assure with high probability that if one treatment is superior to all other treatments by a specified amount δ, then it will have the largest sample mean and will therefore be selected. With normally distributed measures of immunogenicity, the probability of correct selection depends on the ratio of δ/σ and on the number of treatment arms. If there is one best arm and the rest are inferior by δ, then the probability of correct selection decreases as the number of arms increases. Table 3 Another approach to establishing sample size for randomized selection designs is based on the assumption that the true mean immunogenicity for a regimen can be regarded as a random draw from some hypothetical super-distribution of activity levels (17, 18) . By studying more regimens in a randomized trial, one has a greater chance of including a very active regimen. If the number of patients available for the trial is fixed, there is a trade-off between the number of arms in the trial and the number of patients per arm. If we assume that the super-distribution is normal with mean µ and standard deviation ν, then we can compute the expected mean immunogenicity level for the regimen that has the best sample mean in the randomized K arm selection trial. Table 4 design is similar to the phase III design in the respect that it contains a control group for evaluating the experimental regimen and the intent is comparative.
Statistical power for detecting a specified reduction of the hazard of an event is determined by the number of events, not the number of patients. The number of events required to have power 1-β for detecting a treatment effect of size δ with a one-sided statistical significance level of α is approximately:
where δ is the ratio of median survivals to be detected if the survival distributions are exponential (19) . In the calculation of the previous paragraph, δ=1.67, α=0.10, β=0.20
and consequently E = 35 events. The number of patients needed to obtain 35 total events depends on the accrual rate, accrual period and follow-up period. With a slowly progressive disease, it may take many patients to be entered in order to observe a specified number of events unless the follow-up time following the close of accrual is very long. If the disease is rapidly progressive and all patients are followed until progression, then only 35 patients need to be randomized to observe 35 events.
Two different vaccine regimens can be evaluated in a randomized controlled phase II trial with time to progression endpoint by utilizing a three arm design. One arm would be the control group that does not receive either vaccine. For separate evaluation of each vaccine group without adjustment of the significance level for the fact that two vaccines are being evaluated, the number of events and patients required increases by one third compared to the two-arm trial. For example, if 44 patients per arm are required for the two-arm trial above, then 44 patients per arm are required for the three arm trial.
Trials using time to progression endpoints can be terminated early if interim results are not promising. One simple strategy is to perform an interim analysis when half of the planned total number of events have been observed. Accrual can be terminated if the number of events in the treatment group is greater than the number of events in the control group at that time. This interim analysis does not effect the type 1 error rate and causes negligible loss in statistical power (20) . More sophisticated and efficient interim analysis plans for early termination when results are not promising are also possible (21) .
For a trial with multiple vaccine arms and one control arm, the interim monitoring can be used to evaluate each vaccine arm and stop accrual to those for which results are not promising.
Randomized phase 2.5 trials may be structured so that all patients first receive tumor reduction with other modalities prior to randomization.
Phase III Trials
Phase III trials are generally randomized comparisons of a new regimen compared to a standard treatment using an endpoint of established medical importance to the patient such as survival or quality of life. Phase III trials of therapeutic cancer vaccines do not differ in important respects from phase III trials of conventional treatments; a randomized trial is required in both cases with a medically relevant endpoint and an appropriate control group.
Summary
Therapeutic Randomized screening studies can be used to efficiently optimize vaccine immunogenicity. Efficiency in use of patients depends on having assay variation and inter-patient variability small relative to the difference in immunogenicity to be detected.
Phase II studies using time to progression as endpoint are most interpretable if they employ randomized designs with a no-vaccine control group. Such designs may use an inflated type 1 error rate, and need not be prohibitively large if patients with rapidly progressive disease are studied. Interim monitoring plans may effectively limit the size of the trials by terminating accrual early when results are not consistent with the targeted improvement. Table 4 
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